Vaxthera is born, a company that will contribute to the independence of biologicals for Colombia and the region through the research and production of new vaccines, creating new opportunities for the health of Latin Americans. Seguros SURA has invested USD 54 million in this great step, which also translates into new knowledge that ensures we can meet the challenges of the future, thanks to the most recent technological and scientific advances.

Faced with the need that all people in the world have to acquire immunity against COVID 19, especially in Latin America, the company has been created of biologicals and vaccines Vaxthera, which will not only develop drugs against the current virus, but also against those such as yellow fever, dengue, influenza, Zika, and chikungunya.

Led by Jorge Emilio Osorio and made up of scientists, specialists and professionals with more than three decades of experience, this new company will generate 500 jobs and produce more than 100 million doses per year. will benefit Latin America by promoting greater access and equity in the region for immunity against current viruses, for which we have the necessary knowledge and technology that will guarantee quality and protection for our health.

Pharmaceutical, biological and scientific research development benefits us all, taking into account that vaccination, according to the World Health Organization (OMS), "It is a safe and effective way to prevent diseases, which saves three million lives worldwide each year.”

To SURA, having this new company is to strengthen the autonomy of the region and enhance scientific and medical progress for the health of all Latin Americans, who today can have medicines and immunity closer to home, through the development of a leading company in trends and risk management that today invests in the democratization of biologicals for all of Latin America.